Among patients with previously untreated advanced NSCLC with EGFR mutation, osimertinib yielded a longer OS of 38.6 months than a comparator EGFR-TKI (31.8 months) 15. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.